IL277253A - Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (bos) - Google Patents
Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (bos)Info
- Publication number
- IL277253A IL277253A IL277253A IL27725320A IL277253A IL 277253 A IL277253 A IL 277253A IL 277253 A IL277253 A IL 277253A IL 27725320 A IL27725320 A IL 27725320A IL 277253 A IL277253 A IL 277253A
- Authority
- IL
- Israel
- Prior art keywords
- bos
- treatment
- bronchiolitis obliterans
- obliterans syndrome
- cyclosporine formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862656226P | 2018-04-11 | 2018-04-11 | |
| EP18172067 | 2018-05-14 | ||
| PCT/EP2019/058958 WO2019197406A1 (en) | 2018-04-11 | 2019-04-09 | Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (bos) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL277253A true IL277253A (en) | 2020-10-29 |
| IL277253B1 IL277253B1 (en) | 2023-12-01 |
| IL277253B2 IL277253B2 (en) | 2024-04-01 |
Family
ID=66049232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL277253A IL277253B2 (en) | 2018-04-11 | 2019-04-09 | Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (bos) |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11484566B2 (en) |
| EP (1) | EP3773664B1 (en) |
| JP (1) | JP2021520396A (en) |
| CN (1) | CN112105374A (en) |
| AU (1) | AU2019253137A1 (en) |
| BR (1) | BR112020020564A2 (en) |
| CA (1) | CA3094891A1 (en) |
| CO (1) | CO2020013427A2 (en) |
| IL (1) | IL277253B2 (en) |
| MX (1) | MX2020010738A (en) |
| WO (1) | WO2019197406A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3069711A1 (en) * | 2015-03-16 | 2016-09-21 | PARI Pharma GmbH | Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection |
| CN112105374A (en) * | 2018-04-11 | 2020-12-18 | 呼吸治疗公司 | Cyclosporine formulations for the treatment of Bronchiolitis Obliterans Syndrome (BOS) |
| US10736847B2 (en) * | 2018-07-03 | 2020-08-11 | Becton, Dickinson And Company | Inverting device for liposome preparation by centrifugation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020006901A1 (en) | 1999-02-05 | 2002-01-17 | Aldo T. Iacono | Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease |
| EP1438019A1 (en) | 2001-10-24 | 2004-07-21 | PARI GmbH Spezialisten für effektive Inhalation | Kit for the preparation of a pharmaceutical composition |
| DE102006051512A1 (en) | 2005-12-06 | 2007-06-14 | Pari GmbH Spezialisten für effektive Inhalation | Pharmaceutical drug compositions with cyclosporin |
| EP3069711A1 (en) * | 2015-03-16 | 2016-09-21 | PARI Pharma GmbH | Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection |
| CN112105374A (en) * | 2018-04-11 | 2020-12-18 | 呼吸治疗公司 | Cyclosporine formulations for the treatment of Bronchiolitis Obliterans Syndrome (BOS) |
-
2019
- 2019-04-09 CN CN201980025434.8A patent/CN112105374A/en active Pending
- 2019-04-09 EP EP19715929.6A patent/EP3773664B1/en active Active
- 2019-04-09 WO PCT/EP2019/058958 patent/WO2019197406A1/en unknown
- 2019-04-09 IL IL277253A patent/IL277253B2/en unknown
- 2019-04-09 JP JP2020555145A patent/JP2021520396A/en active Pending
- 2019-04-09 CA CA3094891A patent/CA3094891A1/en active Pending
- 2019-04-09 BR BR112020020564-8A patent/BR112020020564A2/en unknown
- 2019-04-09 MX MX2020010738A patent/MX2020010738A/en unknown
- 2019-04-09 US US17/046,307 patent/US11484566B2/en active Active
- 2019-04-09 AU AU2019253137A patent/AU2019253137A1/en active Pending
-
2020
- 2020-10-26 CO CONC2020/0013427A patent/CO2020013427A2/en unknown
-
2022
- 2022-09-26 US US17/935,140 patent/US11701403B2/en active Active
-
2023
- 2023-05-23 US US18/321,788 patent/US20230364182A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3094891A1 (en) | 2019-10-17 |
| CN112105374A (en) | 2020-12-18 |
| EP3773664B1 (en) | 2024-05-01 |
| US11484566B2 (en) | 2022-11-01 |
| IL277253B2 (en) | 2024-04-01 |
| BR112020020564A2 (en) | 2021-01-12 |
| WO2019197406A1 (en) | 2019-10-17 |
| US20230128855A1 (en) | 2023-04-27 |
| AU2019253137A1 (en) | 2020-11-05 |
| MX2020010738A (en) | 2020-11-09 |
| CO2020013427A2 (en) | 2020-11-10 |
| EP3773664A1 (en) | 2021-02-17 |
| JP2021520396A (en) | 2021-08-19 |
| US20230364182A1 (en) | 2023-11-16 |
| IL277253B1 (en) | 2023-12-01 |
| US20210077573A1 (en) | 2021-03-18 |
| US11701403B2 (en) | 2023-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277253A (en) | Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (bos) | |
| IL283948A (en) | Methods for the treatment of depression | |
| IL268125A (en) | Use of pridopidine for the treatment of fragile x syndrome | |
| IL289975A (en) | Use of cannabidiol in the treatment of dravet syndrome | |
| IL290991A (en) | Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease | |
| IL287704A (en) | Use of cannabidiol in the treatment of tuberous sclerosis complex | |
| EP3044229A4 (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| IL285265A (en) | Triamterene or nolatrexed for use in the treatment of phenylketonuria | |
| ZA202102991B (en) | Silicic acids for use in the treatment of periodontitis | |
| IL283229A (en) | High concentration protein formulation | |
| IL281016A (en) | Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| IL286533A (en) | Compounds for use in the treatment of adcy5-related dyskinesia | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| IL286000A (en) | Esketamine for the treatment of depression | |
| EP3870180C0 (en) | Combination comprising sildenafil for use in the treatment of osteoarthritis | |
| EP3761990A4 (en) | Compositions for the treatment of infections in feet | |
| PL3618806T3 (en) | Compositon for the treatment of aphthas and mouth ulcers | |
| GB201901130D0 (en) | Formulation for the treatment of tendinopathies | |
| GB201915517D0 (en) | Use of cannabidiol preparations in the treatment of fragile X syndrome | |
| SG11202100269VA (en) | Compounds for use in the treatment of fascioliasis | |
| IL289425A (en) | A composition of cannabidiol for use in the treatment and prevention of bronchiolitis obliterans | |
| HK1257288A1 (en) | Use of inhibitors of the activity or function of pi3k for the treatment of primary sjögren's syndrome | |
| EP3890765A4 (en) | Methods and compositions for the treatment of sengers syndrome | |
| GB201917493D0 (en) | methods for the treatment of uveal melanoma |